Saturday, October 3, 2026

currencies

3 articles

Dollar Index Drops 10.8% as Global Currency Markets Realign

Dollar Index Drops 10.8% as Global Currency Markets Realign

The U.S. Dollar Index fell 10.8% in early 2026, continuing a shift that saw the euro rise 14% in 2025. The British pound gained 7% in 2025 but dropped to €1.13 by November 2026, its weakest level against the euro since April 2023.

LM Salvado•
Dollar Rebounds From 2022 Lows as Pound Hits $1.3086 on UK Budget Fears

Dollar Rebounds From 2022 Lows as Pound Hits $1.3086 on UK Budget Fears

The dollar recovered from its lowest level since 2022 as the British pound fell to $1.3086 ahead of Chancellor Rachel Reeves' November 26 budget. UK 30-year gilt yields reached 5.21%, the highest since 1998, while global currency markets face uncertainty from Fed leadership transition and geopolitical tensions.

ViaNews Editorial Team•
Dollar Hits 2022 Low as Euro Surges 14%, Reshaping $6.6 Trillion Daily FX Market

Dollar Hits 2022 Low as Euro Surges 14%, Reshaping $6.6 Trillion Daily FX Market

The US dollar fell to its lowest level since 2022, with the euro gaining 14% in 2025 and the British pound up 7%. The currency shift affects $6.6 trillion in daily foreign exchange transactions as central banks from Frankfurt to London navigate diverging monetary pressures ahead of a Federal Reserve leadership transition in June 2026.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com